COVID-19 | Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for Covid-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.

Novavax said last week its experimental vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial...